All news

Everolimus posts 'big win'

Added: Thursday 3 November 2011

Results presented at ECCO suggest a marked improvement in progression-free breast cancer survival when everolimus was added to letrozole, compared to letrozole alone. The BOLERO-2 trial was carried out on women with endocrine-resistant metastatic breast cancer.

+  http://www.oncologystat.com/news/Everolimus_Posts_Big_Win_in_ER-Positive_Breast_Cancer__US.html


//